Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies?

Mick R, Begg CB, Antman KH, Korzun AH, Frei E 3rd.

Breast Cancer Res Treat. 1989 Jan;13(1):33-8.

PMID:
2650758
[PubMed - indexed for MEDLINE]
2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
3.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, J├Ânsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
[PubMed - indexed for MEDLINE]
4.

A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).

Kasimir-Bauer S, Oberhoff C, Schindler AE, Seeber S.

Int J Oncol. 2002 May;20(5):1027-34. Review.

PMID:
11956600
[PubMed - indexed for MEDLINE]
5.

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.

McGuire WP.

Curr Probl Cancer. 1998 May-Jun;22(3):135-77. Review.

PMID:
9659570
[PubMed - indexed for MEDLINE]
6.

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer.

Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL Jr, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff SN, Gale RP, Armitage JO, Vaughan WP, Spitzer G, Horowitz MM.

JAMA. 1999 Oct 13;282(14):1335-43.

PMID:
10527180
[PubMed - indexed for MEDLINE]
7.

Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.

Gago FE, Tello OM, Diblasi AM, Ciocca DR.

J Steroid Biochem Mol Biol. 1998 Dec;67(5-6):431-7.

PMID:
10030692
[PubMed - indexed for MEDLINE]
8.

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

Breast Cancer Res. 2008;10(5):R86. doi: 10.1186/bcr2156. Epub 2008 Oct 16.

PMID:
18925950
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

PMID:
18812550
[PubMed - indexed for MEDLINE]
Free PMC Article
10.
11.

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N.

J Natl Cancer Inst Monogr. 2001;(30):62-6.

PMID:
11773294
[PubMed - indexed for MEDLINE]
12.
13.

[Clinical characteristics and prognosis of breast cancer patients with vascular invasion].

Zhao WH, Xu BH, Zhang P, Li Q, Zhao LM, Sun Y.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):137-40. Chinese.

PMID:
17645853
[PubMed - indexed for MEDLINE]
14.

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.

Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E 3rd, Elias A.

J Clin Oncol. 1995 Aug;13(8):2043-9.

PMID:
7636547
[PubMed - indexed for MEDLINE]
15.
16.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

PMID:
17430582
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.

Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T.

Int J Oncol. 1998 May;12(5):1117-25.

PMID:
9538138
[PubMed - indexed for MEDLINE]
18.

Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.

Dhodapkar MV, Ingle JN, Cha SS, Mailliard JA, Wieand HS.

Cancer. 1996 Feb 15;77(4):683-90.

PMID:
8616760
[PubMed - indexed for MEDLINE]
19.

Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation.

Vij R, DiPersio J, Brown R, Trinkaus K, Abboud C, Meehan KR, Frenette G, Freytes C, Goodnough LT, Khoury H, Ponnuri J, Adkins D.

Bone Marrow Transplant. 2000 Nov;26(9):947-53. Review.

PMID:
11100273
[PubMed - indexed for MEDLINE]
Free Article
20.

Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.

Nistic├▓ C, Cuppone F, Bria E, Fornier M, Giannarelli D, Mottolese M, Novelli F, Natoli G, Cognetti F, Terzoli E.

Anticancer Drugs. 2006 Nov;17(10):1193-200.

PMID:
17075319
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk